Journal Article

The Role of Ranolazine in Heart Failure-Current Concepts

Kourampi, Islam, Siasos, Gerasimos, Tousoulis, Dimitris, Kalogeras, Konstantinos, Tsigkou, Vasiliki, Marinos, Georgios, Katsarou, Ourania, Theofilis, Panagiotis, Oikonomou, Evangelos, Vavuranakis, Manolis, Tsatsaragkou, Aikaterini, Katsioupa, Maria, Goliopoulou, Athina

2023

Overview

Heart failure is a complex clinical syndrome with a detrimental impact on mortality and morbidity. Energy substrate utilization and myocardial ion channel regulation have gained research interest especially after the introduction of sodium-glucose co-transporter 2 inhibitors in the treatment of heart failure. Ranolazine or N-(2,6-dimethylphenyl)-2-(4-[2-hydroxy-3-(2-methoxyphenoxy) propyl] piperazin-1-yl) acetamide hydrochloride is an active piperazine derivative which inhibits late sodium current thus minimizing calcium overload in the ischemic cardiomyocytes. Ranolazine also prevents fatty acid oxidation and favors glycose utilization ameliorating the “energy starvation” of the failing heart. Heart failure with preserved ejection fraction is characterized by diastolic impairment; according to the literature ranolazine could be beneficial in the management of increased left ventricular end-diastolic pressure, right ventricular systolic dysfunction and wall shear stress which is reflected by the high natriuretic peptides. Fewer data is evident regarding the effects of ranolazine in heart failure with reduced ejection fraction and mainly support the control of the sodium-calcium exchanger and function of sarcoendoplasmic reticulum calcium adenosine triphosphatase. Ranolazine's therapeutic mechanisms in myocardial ion channels and energy utilization are documented in patients with chronic coronary syndromes. Nevertheless, ranolazine might have a broader effect in the therapy of heart failure and further mechanistic research is required.

• Publisher: Elsevier Inc,Elsevier Limited
• Subject: Acetanilides - pharmacology / Acetanilides - therapeutic use / Adenosine / Apoptosis / Blood pressure / Calcium / Cardiomyocytes / Cardiovascular disease / Collagen / Congestive heart failure / Cytokines / Cytotoxicity / Diabetes / Diastolic pressure / Ejection fraction / Energy resources / Energy utilization / Glucose transporter / Heart failure / Heart Failure - drug therapy / Humans / Inflammation / Ion channels / Ischemia / Kinases / late sodium current / Morbidity / myocardial metabolism / Myocarditis / Na+/Ca2+ exchanger / Nervous system / Neutrophils / Oxidation / Pathogens / Pathophysiology / Peptides / Phosphorylation / Piperazine / Piperazines - pharmacology / Piperazines - therapeutic use / Proteins / ranolazine / Ranolazine - therapeutic use / Sodium / Substrates / Tumor necrosis factor-TNF / Ventricle / Wall shear stresses